What GHO Capital does

GHO Capital (Global Healthcare Opportunities) is a London-headquartered specialist healthcare private equity adviser founded in 2014 by Managing Partners Mike Mortimer, Alan MacKay and Andrea Ponti together with Co-Founders Sir Dennis Gillings and Lady Mireille Gillings. Operating through GHO Capital Partners Advisory Ltd. (FCA-authorised) and GHO Capital Management Limited, the firm manages four flagship private equity funds totalling c. €9 billion of AUM across BioPharma, MedTech, Life Science Tools & Diagnostics, Advisory & Data and HealthTech, and has built 19 transatlantic/global platforms supported by 70+ strategic add-ons across 200+ international locations.

The firm's core "product" is its specialist healthcare investment platform: a thematic sub-sector origination model, an operating playbook covering internationalisation, M&A and organisational build-out, and an embedded network of Operating Partners, Senior Advisers and a Purpose Advisory Council that supports portfolio companies across the healthcare value chain. Recent and current portfolio companies include Scientist.com (AI R&D orchestration), FotoFinder Systems (AI dermoscopy and skin imaging), Sapio Sciences (lab informatics), Alcami Corporation (CDMO), Avid Bioservices (biologics CDMO), Velocity Clinical Research (clinical trial sites), RoslinCT (cell and gene therapy CDMO), ELIQUENT Life Sciences (regulatory and quality consulting) and ClearView Healthcare Partners (pharmaceutical strategic consulting), with exits including Biocare Medical ($950m sale to Agilent Technologies), VISUfarma (sale to Lupin), BioAgilytix, DDC, Quotient Sciences and Caprion Biosciences.

GHO makes money through traditional private equity economics — recurring fund management and advisory fees charged on committed and invested capital across Funds I–IV, supplemented by performance-based carried interest on successful exits. Capital is raised from more than 50 institutional limited partners globally (pension funds, insurance funds, sovereign wealth funds, financial institutions, endowments and family offices), with Fund IV adding over 30 new institutional investors across Europe, North America, Asia-Pacific and the Middle East. Distribution is relationship-driven: senior partner-led origination for portfolio investments, direct institutional LP engagement, and placement-agent-supported fundraising (Rede Partners advised on Fund IV). In May 2026 GHO signed a definitive agreement to merge with Singapore-based CBC Group, creating the world's largest dedicated healthcare investment manager with over US$21 billion in combined AUM across 13 offices and 200+ professionals, expected to close in early 2027; the combined firm intends to expand into private credit and real estate strategies in addition to private equity.

Name

GHO Capital

Legal name

GHO Capital Partners Advisory Ltd.

Website

http://ghocapital.com

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

51–100 employees

Short description

GHO Capital is a London-headquartered specialist healthcare private equity adviser managing c. €9 billion of AUM across four flagship funds, investing in BioPharma, MedTech, Life Science Tools & Diagnostics, Advisory & Data and HealthTech for more than 50 institutional LPs worldwide.

Ownership category

akta.pro rank

Product category

Healthcare Private Equity Investment Management

NAICS

Portfolio Management and Investment Advice (523940)

SIC

Investment Advice (6282)

akta.pro primary industry

Primary Fund-of-Funds (Blind-pool FoF) (FSANAGAA)

akta.pro secondary industry

Growth Equity Fund-of-Funds (FSANAGAE)

Keywords

• Healthcare private equity
• Investment advisory services
• Biopharma investment
• Medtech investment
• Asset management

Headquarters

HQ city

London

HQ country

United Kingdom

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

1. Fund management and advisory fees: Recurring management and advisory fees charged on committed/invested capital across GHO's flagship private equity funds (Fund I-IV). Capital is raised from more than 50 institutional limited partners globally, including pension funds, insurance funds, sovereign wealth funds, financial institutions, endowments and family offices.
2. Carried interest / performance fees on fund realizations: Performance-based economics earned upon successful exits of portfolio companies (e.g., Caprion Biosciences, Quotient Sciences, BioAgilytix, DDC, Biocare Medical, VISUfarma) and reinvestment into new platform investments and add-ons.
3. Co-investment and future private credit / real estate strategies: Across €3bn+ of private equity funds and co-investments managed today; the combined firm with CBC Group intends to offer investors access to private equity, private credit and real estate assets focused on healthcare and life sciences.

Pricing tiers

Go-to-market motion3 records

Distribution channels4 records

Marketing channels7 records

Core offering

GHO Capital (Global Healthcare Opportunities) is a specialist healthcare investment advisor and private equity fund manager headquartered in London. It raises and manages flagship healthcare-focused private equity funds (Funds I–IV, with Fund IV closing at over €2.5 billion in October 2025), invests in founder-owned and mid-market healthcare companies across Europe and North America, and supports portfolio growth through an embedded Operating Partners network and a transatlantic scaling playbook.

Product overview

GHO Capital is a specialist healthcare private equity firm (not a software product company) offering a unified platform-plus-modules investment proposition. At its core is the GHO Capital Investment Funds platform — Flagship Funds I through IV managed by GHO Capital Management Limited and advised by FCA-authorised GHO Capital Partners Advisory Ltd., targeting healthcare subsectors (BioPharma, MedTech, Advisory & Data, Life Science Tools & Diagnostics, HealthTech). Layered on top are specialist investment advisory services (transatlantic platform building, M&A execution, operational enhancement) and supporting infrastructure including the eFrontCloud-hosted GHO Capital Investor Portal and the public Insights/News publishing site. The portfolio companies themselves (e.g., Scientist.com as an AI-powered R&D orchestration platform; FotoFinder with AI dermatoscopes; Sapio Sciences as a unified LIMS/ELN/SDMS informatics platform; Alcami as a CDMO) function as named modules/operating businesses within the firm's investment offering.

Differentiator

Problem solved

Functional benefit

Brands

• Scientist.com: AI-enabled R&D orchestration platform for life sciences, owned by GHO Capital portfolio.
• FotoFinder Systems
• VISUfarma
• Sapio Sciences
• BioAgilytix
• Caprion Biosciences

Products and services

• GHO Capital Investment Funds (Funds I–IV) Flagship private equity funds offered to institutional limited partners (pension funds, insurance funds, sovereign wealth funds, financial institutions, endowments, family offices) for investment into European and transatlantic healthcare opportunities across BioPharma, MedTech, Advisory & Data, Life Science Tools & Diagnostics and HealthTech sub-sectors.
• Specialist Healthcare Investment Advisory Specialist healthcare investment advisory services provided to portfolio companies and limited partners, covering sector-specialist due diligence, transatlantic platform building, M&A execution, internationalisation support and operational enhancement for mid-market and founder-owned healthcare businesses in Europe and North America.

Quantifiable outcome

• Caprion Biosciences: 85% growth in bookings and growth from 95 to 280 FTEs over three-year hold; 3 bolt-on acquisitions added 5 new geographies.
• +5 more outcomes

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Five partnerships are on record, tiered flagship — transformational merger to create the world's largest dedicated healthcare investment manager, core — strategic buyer of biocare medical portfolio company, minor — portfolio-level transaction with ardena, core — strategic buyer of visufarma portfolio company and strategic — governance and responsible investing oversight.

• CBC Groupflagship — transformational merger to create the world's largest dedicated healthcare investment managerStrategic or Co-development Partner · 20 May 2026CBC Group (Singapore-headquartered Asian healthcare-focused asset manager) signed a definitive agreement with GHO Capital to merge, creating the world's largest dedicated healthcare investment manager with over US$21 billion in combined AUM. Combined firm will have 200+ professionals across 13 offices in North America, Europe and Asia-Pacific. Mike Mortimer (GHO) and Fu Wei (CBC) will serve as Co-CEOs; Andrea Ponti and Alan MacKay (GHO Co-Founders) take board oversight roles for finance and governance respectively; Board co-chaired by Lady Mireille Gillings (GHO) and Fu Wei. Existing funds continue under their current mandates; transaction expected to close in early 2027 subject to regulatory approvals.
• Agilent Technologiescore — strategic buyer of biocare medical portfolio companyStrategic or Co-development Partner · 9 March 2026Agilent Technologies (NYSE:A) agreed to acquire Biocare Medical from Excellere Partners and GHO Capital in an all-cash transaction valued at $950 million. Biocare specialises in immunohistochemistry (IHC), in situ hybridisation (ISH) and fluorescence in situ hybridisation (FISH); Agilent will integrate Biocare into its Life Sciences and Diagnostics Markets Group to expand cancer diagnostics capabilities.
• Catalent (Ardena US footprint deal)minor — portfolio-level transaction with ardenaStrategic or Co-development Partner · 20 November 2025Ardena (GHO portfolio company) signed an agreement to acquire an advanced drug product manufacturing facility from Catalent, expanding Ardena's US footprint. The deal is conducted at the portfolio-company level rather than directly between GHO and Catalent.
• Lupin Limitedcore — strategic buyer of visufarma portfolio companyStrategic or Co-development Partner · 29 September 2025India-headquartered global pharmaceutical major Lupin Limited (through wholly owned subsidiary Nanomi B.V.) signed a definitive agreement to acquire VISUfarma from GHO Capital, with the deal closed on 2 April 2026. VISUfarma brought €48m 2024 revenue and €53m 2025 revenue across Italy, UK, Spain, Germany and France with 60+ branded ophthalmology products, expanding Lupin's European specialty ophthalmology footprint.
• Purpose Advisory Council (chaired by Dame Caroline Mason)strategic — governance and responsible investing oversightOthers · 1 January 2023Independent cross-industry panel supporting GHO Capital's responsible investing strategy, comprising Dame Caroline Mason (CEO Esmée Fairbairn; Chair), Dr. Lisa Hehenberger (Esade Center for Social Impact), Clarke Murphy (former CEO Russell Reynolds; Sustainable Leadership author) and Sacha Romanovich (former CEO Grant Thornton), supported by Andrea Ponti and Robert Saltrick from GHO. The Council supports Funds II, III and IV and reports to the firm formally at least annually.

Scale indicators8 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Andera Partners: European private equity firm (formerly Edmond de Rothschild Investment Partners) with dedicated Life Sciences and Healthcare activities. Closely comparable to GHO as a European-based healthcare specialist mid-market PE manager.
• Ampersand Capital Partners: US-based specialist healthcare and life sciences private equity firm. Directly comparable to GHO as a sector-specialist mid-market PE; co-invests with GHO in Alcami Corporation and Avid Bioservices.
• Linden Capital Partners: US healthcare-focused private equity firm investing in middle-market healthcare companies across services, products and technology. Comparable to GHO as a healthcare specialist PE with a similar sub-sector breadth and mid-market focus.
• Avista Capital Partners: US-based healthcare-focused private equity firm targeting middle-market pharma, medical products and healthcare services. Directly comparable to GHO as a healthcare specialist PE manager in the transatlantic mid-market.
• ArchiMed: European (Lyon-headquartered) private equity firm exclusively dedicated to healthcare, investing across medical products, services and life sciences. Directly comparable to GHO as a pure-play European healthcare specialist PE manager.
• The Vistria Group: US private equity firm with a dedicated healthcare practice. Comparable to GHO as a mid-market investor in healthcare; co-invested alongside GHO in the Alcami Corporation acquisition.
• Excellere Partners: Denver-based private equity firm focused on healthcare and other specialised sectors. Directly comparable to GHO as a healthcare-focused PE; co-owned Biocare Medical with GHO and jointly sold the business to Agilent Technologies for $950m.

Broad incumbents

• BC Partners: European-headquartered global private equity firm with healthcare as a core sector. Comparable to GHO in mid-market healthcare deal-making but offers a broader sector mandate including industrials, consumer and TMT.
• EQT Life Sciences: European private equity firm with a dedicated Life Sciences vertical within a broad multi-strategy platform. Comparable to GHO as a European PE with specialist healthcare exposure, though operating within a much larger and more diversified GP platform.
• Apax Partners: Global private equity firm with a dedicated Healthcare practice. Comparable to GHO in healthcare sub-sector breadth and European mid-market activity, but operates as a generalist across technology, services and consumer as well.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/5248457

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Subsidiaries21 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A19 records

Investments7 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about GHO Capital